As well suited as the name might be to the newly merged company's mission, Mylan didn't have to look far for the Viatris moniker. One of Mylan's subsidiaries acquired three short years ago had already claimed the name Viatris. In July 2016, Mylan snapped up German drugmaker Meda in a $7.2 billion deal aimed at bolstering the drugmaker's OTC franchise. As part of that deal, Mylan also picked up Viatris GmbH, a German specialty drugmaker that Meda snagged in a 2005 deal with private equity firm Advent International valued at $927.5 million.